Johnson & Johnson (J&J) announced that it will invest a total of US$1 B into Elan that will give it an 18.4% stake in the Irish pharmaceutical company. J&J will also pump US$500 M and take over Elan’s joint venture with Wyeth on Alzheimer’s disease, which includes the leading drug in development, bapineuzumab.